Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja
|
October 11, 2005
[Tumor hypoxia:advantage or disadvantage?]
Heikki Minn, Panu Jaakkola
Nucleic Acids Research
|
August 13, 2015
ROTS: reproducible RNA-seq biomarker detector-prognostic markers for clear cell renal cell cancer
Fatemeh Seyednasrollah, Krista Rantanen, Panu Jaakkola, et al.
Journal of Gastrointestinal Cancer
|
February 24, 2017
Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records
Eetu Heervä, Maija Lavonius, Panu Jaakkola, et al.
Cancers
|
February 24, 2024
Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study
Saana Virtanen, Heidi Pihlman, Maria Silvoniemi, et al.
International Journal of Radiation Biology
|
July 30, 2009
Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck
Marjaana Luukkaa, Terhi Jokilehto, Pauliina Kronqvist, et al.
The Biochemical Journal
|
April 24, 2004
Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases
Jan H Marxsen, Petra Stengel, Kathrin Doege, et al.
Cancer Medicine
|
February 24, 2024
Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma
Lassi Luomala, Kalle Mattila, Paula Vainio, et al.
Plos One
|
November 16, 2013
Continuous hypoxic culturing of human embryonic stem cells enhances SSEA-3 and MYC levels
Elisa Närvä, Juha-Pekka Pursiheimo, Asta Laiho, et al.
JAMA Oncology
|
May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2021
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Reetta Virtakoivu, Jenna H Rannikko, Miro Viitala, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Duodecim; Laaketieteellinen Aikakauskirja
|
October 11, 2005
[Tumor hypoxia:advantage or disadvantage?]
Heikki Minn, Panu Jaakkola
Nucleic Acids Research
|
August 13, 2015
ROTS: reproducible RNA-seq biomarker detector-prognostic markers for clear cell renal cell cancer
Fatemeh Seyednasrollah, Krista Rantanen, Panu Jaakkola, et al.
Journal of Gastrointestinal Cancer
|
February 24, 2017
Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records
Eetu Heervä, Maija Lavonius, Panu Jaakkola, et al.
Cancers
|
February 24, 2024
Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study
Saana Virtanen, Heidi Pihlman, Maria Silvoniemi, et al.
International Journal of Radiation Biology
|
July 30, 2009
Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck
Marjaana Luukkaa, Terhi Jokilehto, Pauliina Kronqvist, et al.
The Biochemical Journal
|
April 24, 2004
Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases
Jan H Marxsen, Petra Stengel, Kathrin Doege, et al.
Cancer Medicine
|
February 24, 2024
Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma
Lassi Luomala, Kalle Mattila, Paula Vainio, et al.
Plos One
|
November 16, 2013
Continuous hypoxic culturing of human embryonic stem cells enhances SSEA-3 and MYC levels
Elisa Närvä, Juha-Pekka Pursiheimo, Asta Laiho, et al.
JAMA Oncology
|
May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2021
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Reetta Virtakoivu, Jenna H Rannikko, Miro Viitala, et al.
Page
of 2